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Background
Advances in gene-transfer system and in-depth under-
standing of immune mechanism have made the immu-
notherapy a powerful tool for fighting against cancers.
Recent studies demonstrated a therapeutic potential of
T cells with chimeric antigen receptor (CAR) targeting
CD19 in refractory hematopoietic malignancies. At the
same time, however, hence the CD19 targeting results in
normal cell destruction such as B cell aplasia, a novel mar-
ker that specifically expressed in malignant B cells should
be applied. In this study, we developed anti-malignancy
variant receptor (MVR) mAb that exclusively bound to
malignant B cells but not to normal B cells, and demon-
strated that autologous T cells expressing CAR construct
with anti-MVR scFv (MVR-CAR T cells) efficiently sup-
pressed the outgrowth of malignant B cells in lymphoid
organs.
Results
Malignant B cell-specific monoclonal antibody was iso-
lated from the Balb/c mice immunized with Burkitt’s
lymphoma cell line, L3055. The antibody specifically
recognized the established B lymphoma cell lines and
malignant B cells derived from acute lymphoblastic leu-
kemia, chronic lymphocytic leukemia, and diffuse large
B cell lymphoma patients. Q-TOF analysis revealed that
anti-MVR mAb recognized one of the CD74 variants
that distinctively expressed in malignant B cells. We
used anti-MVR mAb to generate CAR T cells for the
rapid and efficient production of autologous T cells tar-
geting malignant B cells. MVR-CAR T cells were gener-
ated by stimulating T cells with anti-CD2, CD3, CD28
Ab-coated beads and transducing MVR-CAR construct
using lentiviral vector system. Autologous MVR-CAR
T cells efficiently induced cytotoxicity against EBV-
transformed LCLs but not against the normal CD19+ B
cells in vitro. Furthermore, when the MVR-CAR T cells
were adoptively transferred into immune-deficient
RAG2-/-gc-/- mice into which LCLs were subcutaneously
injected 3 weeks previously, they efficiently suppressed
the outgrowth of metastasized LCLs in secondary lym-
phoid organs in vivo.
Conclusions
We developed anti-MVR mAb - a novel malignant B
cell-specific antibody. Anti-MVR mAb recognized one
of CD74 variants that exclusively expressed on malig-
nant B cells. MVR-CAR T cells successfully induced
LCL-specific cytotoxicity in vitro and in vivo. Consider-
ing the unique specificity on malignant B cells, anti-
MVR mAb can be a therapeutic of B cell malignancies
without normal B cell destruction.
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